How much does Glipizide (Glipizide) lower Hemoglobin A1c (HbA1c) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

HbA1c Reduction with Glipizide

Glipizide lowers HbA1c by approximately 1.0 to 1.5 percentage points when used as monotherapy in patients with type 2 diabetes. 1

Expected HbA1c Reduction

  • As monotherapy, glipizide (a sulfonylurea) reduces HbA1c by an average of 1 percentage point, consistent with most diabetes medications used as single agents 2

  • The specific range for glipizide is 1.0% to 1.5% reduction in HbA1c levels 1

  • This glucose-lowering effect is achieved through stimulation of insulin release from pancreatic β-cells 1

Comparative Effectiveness

Monotherapy Comparisons

  • Glipizide demonstrates similar efficacy to other sulfonylureas, with glyburide requiring lower total doses (10 mg vs 16.8 mg) to achieve comparable HbA1c control 3

  • When compared to gliclazide modified release, both agents reduced HbA1c from approximately 8.4% to 7.2%, with approximately 50% of patients achieving HbA1c <7% 4

  • In patients with end-stage renal disease on dialysis, glipizide monotherapy reduced HbA1c by 0.87% over 54 weeks (from baseline of 7.8%) 5

Combination Therapy

  • When combined with metformin, glipizide provides an additional 1.0 percentage point reduction in HbA1c (mean difference 1.00 percentage point [95% CI, 0.75 to 1.25]) compared to metformin alone 2

  • In patients inadequately controlled on sulfonylurea monotherapy, switching to glipizide/metformin combination achieved mean HbA1c reductions of approximately 1.06% greater than glipizide alone 6

  • With combination therapy, 36.3% of patients achieved HbA1c <7.0%, compared to only 8.9% with glipizide monotherapy 6

Important Clinical Considerations

Baseline HbA1c Impact

  • The magnitude of HbA1c reduction is greater when baseline HbA1c is higher 7

  • Patients with baseline HbA1c >9% may experience reductions approaching 2% or more with combination therapy 7

Safety Profile

  • Hypoglycemia is the most common adverse effect, particularly in elderly patients and those with hepatic or renal dysfunction 1

  • Glipizide causes weight gain, averaging 2.7 kg more than metformin monotherapy 2

  • In comparative studies, glipizide showed higher rates of severe hypoglycemia (7.7%) compared to sitagliptin (0%) in dialysis patients 5

Common Pitfalls to Avoid

  • Do not expect additive HbA1c reductions when combining agents—the second agent typically provides less reduction than when used as monotherapy because it starts from a lower baseline 7

  • Avoid using glipizide as preferred therapy in patients with established cardiovascular disease or chronic kidney disease, where SGLT2 inhibitors or GLP-1 receptor agonists offer superior cardiovascular and renal protection 8

  • Recognize that newer agents (GLP-1 RAs, SGLT2 inhibitors) may provide similar or superior HbA1c reduction without the risks of hypoglycemia and weight gain associated with sulfonylureas 2, 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.